PumasAI | PumasAI

PumasAI developed a revolutionary platform for model based drug development which utilizes the powerful Julia programming language. Data integration, model specification, and post-processing are easy and convenient. PumasAI product is a breath of fresh air and a real winner.

Robert D. Johnson, PhD

Sr. Pharmacokineticist, P&G Pharmaceuticals

We have a high priority oncology drug development portfolio at our company. PumasAI provided us with high quality MIDD work product which supported regulatory submissions in a timely manner. It is a pleasure to work with PumasAI scientists, and we highly recommend them!

Balaji Agoram, PhD

VP & Head of Clinical Pharmacology, Arcus Biosciences

PumasAI is a valued partner and works very hard to help us achieve our goal. I would recommend PumasAI highly.

Jinshan Shen, PhD

VP & Head of Clinical Pharmacology, Relay Therapeutics

PumasAI worked with us with incredible flexibility and agility despite tight timelines and sometimes the need for re-work or additional evaluation, as often is the case with data driven exercises. Overall, a great experience and looking forward to working with them again.

Samira Merali, PharmD, MS

Sr. Director & Cardiovascular Therapeutic Head, Clinical Pharmacology and Pharmacometrics, BMS

Recently we worked with Dr Gobburu and his team on applying Model-informed Drug Development (MIDD) approach to support the development of one of our key assets. This work led to a successful meeting with the FDA and shortening the drug development program tremendously.

Dr Anil Namboodiripad, PhD

Sr. Vice President, Proprietary Products, Dr. Reddy's Laboratories Limited

We have been using Pumas software for our pharmacometric needs to support our development decisions and regulatory submissions. Pumas software has surpassed our expectations on its accuracy and ease of use.

Husain A. PhD

Director, Head of Clinical Pharmacology and Pharmacometrics, Moderna Therapeutics, Inc

The professionalism, collegiality, and unparalleled drug development acumen are some of the biggest differentiators that we see with the PumasAI, Inc.. We are already working on an MIDD meeting for another product with PumasAI, Inc. and look forward to continuing our collaborations.

Arash Raoufinia, MS, PharmD

VP Head of Early Phase Development and Translational Medicine at Otsuka Pharmaceutical Companies (U.S.)

The Center for Translational Medicine, University of Maryland, Baltimore, was instrumental in helping us obtain approval from the FDA. The trial involves individualization of patient doses using Pumas software based on non-compartmental analysis and modeling. We look forward to working with Drs. Long-Boyle and Gobburu on this important project.

John Horan MD, MPH

Stem Cell Transplantation Program, Department of Pediatric Oncology, Dana-Farber Cancer Institute Division of Hematology/oncology, Boston Children’s Hospital

The CTM’s Dr. Allison Dunn and Dr. Gobburu have provided timely and high quality scientific analyses and regulatory input to our team. Their analyses have helped us make key internal decisions, and also submitted to multiple regulatory agencies across the world successfully. All the modeling and simulation analyses were conducted using Pumas software.

Marc Ditmarsch, MD

VP Research and Development at Newamsterdam Pharma & Founder Diomedea Medical Bv